CD8A and neoplasm: Although no changes were observed in the Treg population after copanlisib treatment, the shared association of lower baseline levels of CD8+ effector memory cells and circulating IL-2 levels with improved tumor response suggests that reduced IL-2–dependent expansion of effector memory T cells may be predictive of patient outcomes.